openPR Logo
Press release

Orphan Diseases Market – Sketch of Vital Industry Drivers: Pfizer Inc., F. Hoffmann-La Roche Ltd, AbbVie Inc.

10-30-2017 02:13 PM CET | Health & Medicine

Press release from: Market Research Future

Orphan Diseases Market – Sketch of Vital Industry Drivers:

Orphan Diseases Market is expected to grow at the average CAGR of 24.9% constantly throughout this period 2015-2022. It is also expected that this market which was US$ 121.6 billion in 2015 will grow to US$ 576.9 billion by 2022. However due to lack of awareness, correct diagnosis, correct treatments and availability of healthcare facilities are inhibiting the growth of the global orphan diseases market.

Orphan Diseases Market also known as rare disease is growing rapidly. It affects a very small percentage of the global population. Most of the orphan diseases are genetic and is remains throughout the life of the patient. There are no exact number of diseases available but approximately there are about 7000 different rare diseases and disorders throughout the globe.

Get Sample Report @ https://www.marketresearchfuture.com/sample_request/2547 .

Regional Analysis of Global Orphan diseases Market:

Considering the global scenario of this market, North American region is believed to be the largest market of the global orphan diseases market. Moreover the European market is also growing and is the second largest market for global orphan diseases. On the other hand, Asia-Pacific’s orphan disease market is expected to grow at a significant rate during the forecasted period. Rest of the World is likely to have a limited but steady growth with respect to this market.

Study Aim of Global Orphan Diseases Market:

To analyze the global orphan diseases market based on various analyses which includes price analysis, supply chain analysis, Porters Five Force analysis etc.

To provide past and estimated future revenue of the market’s segments and sub segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific and Middle East & Africa.

To provide country level analysis of the market with respect to the current market size and future growth prospect.

To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments in the global orphan diseases market.

To provide detail analysis of the market structure along with forecast for the next 5 years about various segments and sub-segments of the global orphan diseases market.

To provide insights about factors affecting the market growth.

Browse Report @ https://www.marketresearchfuture.com/reports/orphan-diseases-market-2547 .

Competitor for Global Orphan diseases Market:

Pfizer Inc. (US), Alexion (US), Sanofi (French), Vertex Pharmaceuticals Incorporated (US), GlaxoSmithKline plc. (UK), Merck & Co., Inc (US), AbbVie Inc. (US), Bristol-Myers Squibb Company (US), Novartis AG (Switzerland), CELGENE CORPORATION (US), F. Hoffmann-La Roche Ltd (Switzerland),

Market Segmentation:

On the basis of types of diseases which includes autoimmune disorders, genetic disorders, blood disorders, cancer, growth disorder, cardiovascular diseases, neurological disorders, respiratory disorders, digestive disorders, eye disorders and others.

Treatment type it segmented into gene therapy, cell therapy, drug therapy and others.

End user the market is segmented into hospital and clinics, research laboratory and others.

Table of Content:

1 Report Prologue
2 Market Introduction
3 Research Methodology
4 Market Dynamics
5 Market Factor Analysis
6 Global Orphan Diseases Market, By Disease Type (USD Million)
7 Global Chronic Disease Management Market, By Treatment Type (USD Million)
8 Global Chronic Disease Management Market, By End User (USD Million)
9 Global Orphan Disease Market, By Region (USD Million)
10 Company Landscape
11 Company Profiles

List of Tables:

Table 1 Global Orphan Disease Market, 2013-2022 (Usd Million)

Table 2 Global Orphan Disease Market, By Disease Type, 2013-2022 (Usd Million)

Table 3 Global Chronic Disease Management Market, By Tratment Type, 2013-2022 (Usd Million)

Table 4 Global Chronic Disease Management Market, By End User, 2013-2022 (Usd Million)

Table 5 Global Chronic Disease Management Market, By Region, 2013-2022 (Usd Million)

Get Discount for Report @ https://www.marketresearchfuture.com/check-discount/2547 .

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Akash Anand,

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

+1 646 845 9312

Email: akash.anand@marketresearchfuture.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Orphan Diseases Market – Sketch of Vital Industry Drivers: Pfizer Inc., F. Hoffmann-La Roche Ltd, AbbVie Inc. here

News-ID: 793441 • Views:

More Releases from Market Research Future

9-Decanoic Acid Methyl Ester Market Poised for Strong 6.59% CAGR Growth Through 2035
9-Decanoic Acid Methyl Ester Market Poised for Strong 6.59% CAGR Growth Through …
The 9-decanoic acid methyl ester market is a growing sector driven by the increasing demand for bio-based and sustainable chemical products across various industries. With its unique properties, it finds application in flavors and fragrances, pharmaceuticals, personal care, and as a chemical intermediate. The market is projected to expand significantly in the coming years. Market Overview and Size The global 9-decanoic acid methyl ester market was valued at USD 230.0 million in
Washable Marker Market Poised for 3.54% CAGR Growth During 2024-2032
Washable Marker Market Poised for 3.54% CAGR Growth During 2024-2032
The washable marker market is a dynamic and growing segment within the broader stationery and art supplies industry. Driven by a blend of consumer demands for safety, convenience, and sustainability, the market is experiencing consistent expansion, particularly within the education and home-use sectors. While faced with some challenges, the industry's future looks promising, propelled by product innovation and evolving consumer trends. Get Sample @ https://www.marketresearchfuture.com/sample_request/41217 Market Size and Growth The global washable
Phone Car Mounts Market to Reach USD 7.37 Billion by 2034, Growing at 6.47% CAGR
Phone Car Mounts Market to Reach USD 7.37 Billion by 2034, Growing at 6.47% CAGR
The phone car mounts market, a critical sub-segment of the broader automotive accessories industry, is experiencing robust growth driven by a convergence of technological advancements, evolving consumer behavior, and increasingly stringent road safety regulations. As smartphones become indispensable for navigation, communication, and in-car entertainment, the demand for secure and convenient hands-free solutions continues to escalate. The global phone car mounts market was valued at USD 3.93 billion in 2024 and
Intravenous (IV) Solution Market Set to Grow to USD 26.60 Billion at 7.70% CAGR by 2032
Intravenous (IV) Solution Market Set to Grow to USD 26.60 Billion at 7.70% CAGR …
Market Overview: The Intravenous (IV) Solution Market is estimated to be valued at USD 13.9 billion in 2023 and is projected to reach USD 26.60 billion by 2032, expanding at a compound annual growth rate (CAGR) of 7.70% from 2024 to 2031. The market growth is attributed to the rising prevalence of chronic diseases, growing hospitalization rates, and increasing surgical procedures that require IV fluid administration. Intravenous solutions are critical

All 5 Releases


More Releases for Disease

Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research. Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight: Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and